NBIM-1008 / Neurocrine Biosciences - LARVOL DELTA

NBIM-1008-1791: A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis (clinicaltrialsregister.eu) - P1 | N=15 | Not yet recruiting | Sponsor: Neurocrine Biosciences Inc.

First-in-human • New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology